Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

Capecitabine is an oral, tumor‐targeted fluoropyrimidine carbamate with high activity in metastatic breast carcinoma and in paclitaxel‐pretreated metastatic breast carcinoma.

[1]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[2]  E. Eisenhauer,et al.  Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Reigner,et al.  A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours , 2000, British Journal of Cancer.

[4]  H. Burger,et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[6]  B. Reigner,et al.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  B. Reigner,et al.  Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Reigner,et al.  Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients , 1999, Cancer Chemotherapy and Pharmacology.

[9]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Reigner,et al.  A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Reigner,et al.  Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[14]  B. Reigner,et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[16]  B. Reigner,et al.  Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. , 1998, Clinical Cancer Research.

[17]  R. Livingston,et al.  Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Dittrich,et al.  Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study , 1996, Cancer Chemotherapy and Pharmacology.

[20]  V. Valero,et al.  Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Christian,et al.  Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Payne.  A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.

[23]  J. Yahalom,et al.  [Treatment of metastatic breast cancer]. , 1986, Harefuah.

[24]  M. Lippman,et al.  Cancer of the breast. , 1980, The New England journal of medicine.

[25]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[26]  M. Laberge.  [Cancer of the breast]. , 1961, Laval medical.